Patents Assigned to Secretary, DHHS
  • Patent number: 11555013
    Abstract: Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: January 17, 2023
    Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DHHS
    Inventors: Amy Hauck Newman, Oluyomi M. Okunola-Bakare, Jianjing Cao
  • Patent number: 11547708
    Abstract: A composition for preserving viability of cells, tissues, or organs at a low temperature is provided. The composition includes a mitochondrial uncoupling agent, at least one protease inhibitor, and a reducing agent. Methods to protect cells, tissues, or organs from exposure to cold and other metabolic stress are also provided.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: January 10, 2023
    Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DHHS
    Inventors: Jingxing Ou, Wei Li, Kiyoharu Josh Miyagishima
  • Patent number: 11421219
    Abstract: Expression vectors, viral particles and therapeutic methods of using such constructs to improve the visual function of a patient suffering from diseases of the eye, resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye, particularly Leber Congenital Amaurosis (LCA) and CEP290-related LCA.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: August 23, 2022
    Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DHHS
    Inventors: Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna
  • Patent number: 11390651
    Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: July 19, 2022
    Assignees: The USA, Secretary, DHHS, Codagenix, Inc.
    Inventors: Cyril Lenouen, Ursula J. Buchholz, Peter L. Collins, Steffen Mueller
  • Patent number: 11382990
    Abstract: Described herein are X-ray imageable polymers such as polymeric particles comprising bismuth as a radiopacifying agent, methods of making the polymers, and methods of using the polymers. The imageable particles may comprise a covalently bound compound which chelates the bismuth, for example, through a combination of nitrogen and oxygen atoms.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: July 12, 2022
    Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DHHS
    Inventors: Ayele H. Negussie, Bradford Johns Wood
  • Patent number: 10130700
    Abstract: This disclosure provides compositions that include a mixture of viral like particles (VLPs), expressing different individual influenza hemagglutinin (HA) proteins that elicit broadly reactive immune responses to a wide variety of influenza viruses. For example, the composition can include at least two different influenza VLPs, a first VLP comprising a first HA polypeptide and a second VLP comprising a second influenza HA polypeptide, wherein the first and the second HA polypeptide are different subtypes and/or are from different influenza viruses, and a pharmaceutically acceptable carrier and/or an adjuvant. Methods of using the disclosed polymeric influenza VLP compositions to stimulate an immune response against influenza viruses, for example as a pre-pandemic or a seasonal vaccine, are provided.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: November 20, 2018
    Assignee: The United States of America, as represented by the Secretary, DHHS
    Inventor: Jeffery K. Taubenberger
  • Patent number: 9464324
    Abstract: Methods are disclosed for determining the prognosis of a subject with an adenocarcinoma in an organ, such as the lung. The methods can include quantitating expression of a plurality of cytokines of interest, such as IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-? and TNF-a in the adenocarcinoma and in non-cancerous tissue in the organ. Altered expression of IL-1a, IL-1b, IL-2, IL-8, IL-10, IL-12, IL-15, IFN-? and TNF-a in the adenocarcinoma as compared to a control and in non-cancerous tissue in the organ as compared to a control determines the prognosis for the subject. Methods for determining if a therapeutic agent is effective as an anti-cancer agent are also disclosed.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: October 11, 2016
    Assignee: The United States of America as represented by the Secretary, DHHS
    Inventors: Curtis C. Harris, Masahiro Seike, Xin Wei Wang
  • Patent number: 9249217
    Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: February 2, 2016
    Assignees: Secretary, DHHS, Duke University
    Inventors: Darell D. Bigner, Chien-Tsun Kuan, John H. Sampson, Mingqing Cai, Bryan D. Choi, Ira H. Pastan
  • Publication number: 20150203547
    Abstract: The inventors have identified Pfs47, a gene from the malaria parasite P. falciparum, as a key factor for survival of these parasites in the mosquito Anopheles gambiae. A. gambiae is a major natural vector of human malaria in Africa. The Pfs47 protein may allow the parasite to survive in the mosquito by manipulating the mosquito's immune system. The inventors propose the use of P47 proteins, including Pfs47 and Pvs47 as a target of vaccines or pharmaceutical agents that will block or reduce P. falciparum or P. vivax infection in A. gambiae or other anopheline mosquitoes and thus prevent further transmission of the parasites in humans.
    Type: Application
    Filed: August 16, 2013
    Publication date: July 23, 2015
    Applicant: The United States of America, as represented by the Secretary, DHHS
    Inventors: Carolina Veronica Barillas-Mury, Alvaro Molina-Cruz
  • Patent number: 8041412
    Abstract: Systems and methods for obtaining position sensor space data regarding an endovascular prosthesis within an anatomical region of a patient include at least one position indicating element which is movable within an endovascular prosthesis is tracked by a tracking system. A guidance portion of the endovascular prosthesis constrains movement of position indicating elements within the endovascular prosthesis.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: October 18, 2011
    Assignees: Koninklijke Philips Electronics N.V., The United States of America, as represented by the Secretary DHHS
    Inventors: Neil David Glossop, Bradford Johns Wood
  • Publication number: 20090291923
    Abstract: The invention provides novel trioxane dimers having formulae III, IV or V: methods for their preparation, pharmaceutical compositions containing these compounds, and methods for treating cancer and/or malaria using these compounds and compositions.
    Type: Application
    Filed: November 17, 2006
    Publication date: November 26, 2009
    Applicants: Johns Hopkins Universoty, The Government of the United States of America as Represented by the Secretary of the DHHS NIH, Offi
    Inventors: Gary H. Posner, Ikhyeon Paik, Kristina Borstnik, Wonsuk Chang, Sandra Sinishtaj, William Malo, John Gaetano D'Angelo, Lauren Elaine Woodard, Alvin Solomon Kalinda, Aimee R. Usera, Lindsey Catherine Hess, Andrew Scott Rosenthal, Seongho Oh, Astrid C. Baege
  • Publication number: 20090289630
    Abstract: An apparatus for imaging includes: a radio frequency (RF) coil array having a first RF coil and at least one additional RF coil, where the RF coil array is adapted to generate an image signal; a preamplifier having an input impedance, where the preamplifier is adapted to receive the image signal from the first RF coil; and a transformer to couple the first RF coil to the preamplifier, where impedance of the transformer is adapted to match the input impedance of the preamplifier.
    Type: Application
    Filed: April 6, 2007
    Publication date: November 26, 2009
    Applicant: The Government of the United States of America, represented by The Secretary, DHHS
    Inventors: George Nascimento, Afonso C. Silva
  • Publication number: 20090208409
    Abstract: A detection agent, including a polymerized liposome, a lectin, and an imaging agent, can be administered to an animal for the detection of polyps in the lower gastrointestinal tract.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 20, 2009
    Applicant: The Government of the United States of America, as represented by the Secretary, DHHS
    Inventors: Ronald M. Summers, Jianwu Xie, Celeste A. Roney
  • Patent number: 7547712
    Abstract: The present invention relates methods for reducing the adverse effects of nicotine. This application describes the use of nicotine carrier conjugates in decreasing the toxic effects of nicotine on a fetus.
    Type: Grant
    Filed: February 26, 2007
    Date of Patent: June 16, 2009
    Assignees: Nabi Biopharmaceuticals, United States of America as Represented by the Secretary, DHHS Office of Technology Transfer, National Institutes of Health
    Inventors: Sofiane Ennifar, Scott Winston, James Terrill, Steve Fuller
  • Publication number: 20090142332
    Abstract: The present invention relates to methods of determining colorectal cancer status in a subject. The invention further relates to kits for determining colorectal cancer status in a subject. The invention further related to methods of identifying biomarker for determining colorectal cancer status in a subject.
    Type: Application
    Filed: March 22, 2006
    Publication date: June 4, 2009
    Applicant: Government of the US, as represented by the Secretary, DHHS
    Inventors: Thomas Ried, Jens Habermann
  • Publication number: 20090118608
    Abstract: A magnetic resonance imaging scanner acquires diffusion-weighted imaging data. A reconstruction engine reconstructs the acquired diffusion-weighted imaging data into diffusion-weighted image representations. A diffusion tensor engine constructs a diffusion tensor map of an area of an interest of a subject. An eigenvalue/eigenvector ordering engine obtains and orders eigenvectors and eigenvalues at each voxel. A covariance matrix determining engine constructs a covariance matrix of a major eigenvector of each voxel. A first normalized measure determining engine computes a first normalized measure. A second normalized measure determining engine computes a second normalized measure. A rendering engine generates a human-viewable display of an image representation.
    Type: Application
    Filed: November 3, 2008
    Publication date: May 7, 2009
    Applicant: The Government of the United States of America, represented by The Secretary, DHHS
    Inventor: Cheng Guan Koay
  • Publication number: 20060165652
    Abstract: A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted.
    Type: Application
    Filed: September 5, 2003
    Publication date: July 27, 2006
    Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRE- SENTED BY THE SECRETARY DHHS
    Inventors: Mark Dudley, Steven Rosenberg, John Wunderlich
  • Patent number: 5462852
    Abstract: An antigen capture method, and an antigen capture assay diagnostic kit, for detecting the presence or concentration of HIV in a biological sample without interference from antigen-antibody immune complexes is provided. The lysate of a biological sample obtained from an animal is contacted with a detectable amount of an antibody specifically reactive with the nucleocapsid p7 antigen or an immunoreactive fragment of the p7 antigen for a time and under conditions sufficient for p7 antigen contained in the lysate to form a p7-antibody complex. The presence or concentration of this p7-antibody complex is determined to detect or quantitate the presence of HIV in the biological sample. Uses of this assay and method include detecting the presence of HIV infection in an infant born to an HIV-infected mother, monitoring the progression of HIV infection, and evaluating the effectiveness of an anti-HIV treatment administered to an animal, such as a human.
    Type: Grant
    Filed: October 28, 1992
    Date of Patent: October 31, 1995
    Assignee: The Government of the United States of America, as Represented by the Secretary, DHHS
    Inventors: Larry O. Arthur, Louis E. Henderson
  • Patent number: 5441941
    Abstract: Certain new 1,2-dihydroellipticine compounds having activity against CNS specific cancer cell lines because of their ease of passage across the blood-brain barrier are disclosed along with formulations and methods for treating CNS cancers employing these compounds.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: August 15, 1995
    Assignees: The United States of America as represented by the Secretary of DHHS, Purdue Research Foundation
    Inventors: Rudiger D. Haugwitz, Venkatachiala L. Narayanan, Mark Cushman, Jurjus Jurayj
  • Patent number: 5158940
    Abstract: Polysulfonated compounds such as suramin are used to treat immunoregulatory isorders. Particular use in the treatment of rheumatologic diseases such as rheumatoid arthritis is shown.
    Type: Grant
    Filed: February 14, 1990
    Date of Patent: October 27, 1992
    Assignee: The United States Government as represented by the Secretary, DHHS
    Inventors: Renato V. LaRocca, Cy A. Stein, Michael R. Cooper, Charles E. Myers